Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Bavarian Nordic A/S    BAVA   DK0015998017

BAVARIAN NORDIC A/S (BAVA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
281(c) 270.5(c) 278(c) 269(c) 270(c) Last
160 330 312 342 239 344 228 806 163 262 Volume
-1.06% -3.74% +2.77% -3.24% +0.37% Change
More quotes
Financials ( DKK)
Sales 2017 1 172 M
EBIT 2017 353 M
Net income 2017 215 M
Finance 2017 2 035 M
Yield 2017 -
Sales 2018 1 065 M
EBIT 2018 213 M
Net income 2018 334 M
Finance 2018 1 472 M
Yield 2018 -
P/E ratio 2017 40,23
P/E ratio 2018 25,47
EV / Sales2017 5,63x
EV / Sales2018 6,72x
Capitalization 8 635 M
More Financials
Company
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.The company operates its business through the cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast,... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Surperformance© ratings of Bavarian Nordic A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on BAVARIAN NORDIC A/S
10/04 BAVARIAN NORDIC A/S : seals $539 million vaccine deal
10/02 BAVARIAN NORDIC A/S : Secures Contract Award for Supply of Freeze-dried IMVAMUNE..
09/28 BAVARIAN NORDIC A/S : Secures Contract Award for Supply of Freeze-dried IMVAMUNE..
09/28 BAVARIAN NORDIC A/S : eyes more U.S. government contracts after new vaccine orde..
09/27 BAVARIAN NORDIC A/S : Secures Contract Award for Supply of Freeze-dried IMVAMUNE..
09/25 BAVARIAN NORDIC A/S : Provides Update on its Universal RSV Vaccine
09/21 BAVARIAN NORDIC A/S : Provides Update on its Universal RSV Vaccine
09/19 BAVARIAN NORDIC A/S : Independent data monitoring committee recommends discontin..
09/16 BAVARIAN NORDIC A/S : to Host Capital Markets Day in New York City
09/15 BAVARIAN NORDIC A/S : Independent Data Monitoring Committee Recommends Discontin..
More news
Sector news : Pharmaceuticals - NEC
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Pharmaceuticals - NEC
Latest Tweets
10/12SGS and Bavarian Nordic developing challenge strain to combat respiratory vir.. 
10/03Bavarian Nordic gets a lift with smallpox vaccine contract worth up to $539M .. 
10/02Bavarian Nordic gets a lift with smallpox vaccine contract worth up to $539M ..
3
09/28Vaccine order boosts Bavarian Nordic after cancer drug flop
2
09/28Bavarian Nordic eyes more U.S. government contracts after new vaccine order  
More tweets
Qtime:52
News from SeekingAlpha
09/29 Bavarian Nordic (BVNRY) New Barda Contract For Freeze-Dried Imvamune - Slides..
09/22 Bavarian Nordic (BVNRY) Investor Presentation - Slideshow
09/19 Daily OTC Markets Round-Up - 9/18/2017
08/25 Bavarian Nordic A/S's (BVNKF) CEO Paul Chaplin on Q2 2017 Results - Earnings ..
08/25 Bavarian Nordic A/S 2017 Q2 - Results - Earnings Call Slides
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | BAVA | DK0015998017 | 4-Traders
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 309  DKK
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Paul Chaplin President & Chief Executive Officer
Gerardus Wilhelmus van Odijk Chairman
Henrik Birk Chief Operating Officer & Executive Vice President
Ole Larsen Chief Financial Officer & Executive Vice President
Christopher R. Heery Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAVARIAN NORDIC A/S8.63%1 368
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223